SCHEMBL6315281

SCHEMBL6315281

CC(=O)OC[C@H]1O[C@@H](n2cc(F)c(N)nc2=O)[C@H](O)[C@@H]1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALB P02768 1/20 0.41
▸ LMNA P02545 4/20 0.40
▸ POLG P54098 1/20 0.37
▸ P2RY6 Q15077 2/20 0.37
▸ P2RY14 Q15391 2/20 0.37
▸ NT5E P21589 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ MTOR P42345 2/20 0.36
▸ THRB P10828 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ MDM2 Q00987 1/20 0.36
▸ NCOA1 Q15788 1/20 0.36
▸ NCOA3 Q9Y6Q9 1/20 0.36
▸ GMNN O75496 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ DNMT1 P26358 1/20 0.36
▸ THPO P40225 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880873 0.91 LMNA (0.43) ALBLMNAP2RY6P2RY14NT5E
SCHEMBL12724352 0.89 LMNA (0.42) ALBLMNAPOLGP2RY6P2RY14
SCHEMBL11801230 0.87 LMNA (0.45) ALBLMNAALDH1A1MTORTHRB
SCHEMBL10887648 0.86 ALDH1A1 (0.44) ALBLMNAALDH1A1THRBTP53
SCHEMBL10887645 0.86 ALDH1A1 (0.44) ALBLMNAALDH1A1THRBTP53
SCHEMBL2585673 0.84 ALB (0.51) ALBLMNANT5EALDH1A1MTOR
SCHEMBL2583173 0.82 LMNA (0.51) ALBLMNAALDH1A1THRBTP53
SCHEMBL26804271 0.82 LMNA (0.51) ALBLMNAALDH1A1THRBTP53
SCHEMBL3639989 0.82 LMNA (0.51) ALBLMNAALDH1A1THRBTP53
SCHEMBL10894045 0.80 LMNA (0.44) ALBLMNAALDH1A1THRBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927291-B2 Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides PHARMASSET, LTD. (US) 2005-08-09 — — US disclosed
US-20020198224-A1 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides GILEAD PHARMASSET LLC 2002-12-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198224-A1 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides DUT, DUS2, DERA ALB 3713/4885LMNA 696/4885POLG 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback